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Abstract 
Background: Malaria is a major cause of morbidity and mortality in sub-Saharan Africa, and poor outcomes have 
been associated with endothelial activation. In this study, biomarkers of endothelial activation, haemostasis, and 
thrombosis were measured in Ugandan children with severe malaria who participated in a clinical trial, in order to 
investigate associations between these processes.
Methods: Serum and plasma were collected from participants at baseline (day 1), and on days 2, 3, 4, and 14. Von 
Willebrand factor (VWF) antigen was measured in stored plasma samples from all trial participants, and its association 
with mortality and changes over time were analysed. VWF multimer patterns were evaluated in baseline serum sam-
ples by gel electrophoresis followed by Western blotting. Levels of angiopoietins 1 and 2, VWF antigen, total active 
VWF, ADAMTS13, platelet counts, apolipoprotein A1, and syndecan-1 were measured in stored serum samples from 12 
survivors at baseline and day 4.
Results: VWF antigen levels were associated with mortality, and decreased over time in survivors. Baseline VWF anti-
gen and total active VWF levels were elevated, and very large multimers were present in the baseline serum of several 
patients. Higher platelet counts were associated with higher angiopoietin-1 and apolipoprotein A1 levels, while lower 
platelet counts were associated with higher syndecan-1, a marker of endothelial damage. Higher angiopoietin-2 to 
angiopoietin-1 ratio and higher syndecan-1 levels were correlated with lower apolipoprotein A1 levels. There were 
no correlations between total active VWF, VWF antigen, or ADAMTS13 levels and the other biomarkers at baseline. 
Changes in biomarker levels between baseline and day 4 were not correlated.
Conclusions: These results confirm that severe malaria is associated with endothelial activation, and suggest that 
endothelial activation contributes to microvascular thrombosis and endothelial damage.
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Background
Malaria is a major cause of morbidity and mortality in 
sub-Saharan Africa, where over 90 % of all malaria deaths 
occur [1]. Children are most affected, with approximately 
78 % of malaria deaths worldwide occurring in children 
under 5  years of age [1]. While most infections can be 
managed effectively if promptly diagnosed and treated, 
some patients present with severe forms of malaria, 
including cerebral malaria (CM), or worsen despite treat-
ment. Fatality rates for children with severe malaria (SM) 
and CM have been estimated at approximately 8.5 and 
18 % despite treatment with intravenous artesunate, the 
current standard of care [2]. Survivors of CM can develop 
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neurocognitive deficits, including epilepsy, behavioural 
disorders, and motor, sensory or language deficits [3]. 
These outcomes suggest that adjunctive therapy target-
ing mechanistic pathways mediating severe disease is 
needed.
Evidence suggests that the host response plays an 
important role in determining disease severity and out-
comes [4, 5]. Systemic inflammation in SM is associated 
with endothelial activation and expression of adhesion 
molecules that can amplify inflammatory signals [6]. 
Endothelial activation involves dysregulation of the 
angiopoietin/receptor tyrosine kinase Tie2 (Ang/Tie2) 
axis [7], as well as the release of Von Willebrand Factor 
(VWF) from secretory granules known as Weibel–Palade 
bodies. VWF is an important multimeric protein neces-
sary for normal haemostasis; when dysregulated, VWF 
can cause devastating microvascular thrombosis [8]. 
Elevated VWF levels have been reported in children with 
asymptomatic parasitaemia [9], suggesting that malaria 
parasites induce a state of endothelial activation even at 
early stages of infection.
VWF is normally cleaved from the surface of endothe-
lial cells by the activity of ADAMTS13, a zinc-containing 
metalloprotease [10]. In malaria, however, ADAMTS13 
activity is reduced and VWF can persist and self-asso-
ciate into large multimers which can bind platelets [8]. 
These bound platelets can accumulate on the endothelial 
surface, causing thrombi and leading to vessel occlusion 
[11]. Systemic endothelial activation in SM is also accom-
panied by a reduced plasma or serum concentration of 
apolipoprotein A1 (ApoA1), the primary protein com-
ponent of high-density lipoprotein (HDL) particles [12]. 
Published work by the authors of this paper has demon-
strated that plasma HDL and ApoA1 dose-dependently 
decrease the extent of VWF self-association, in the pro-
cess also significantly decreasing the binding of platelets 
to the vessel wall [13]. ApoA1 levels may, therefore, be 
protective in SM. Conversely, syndecan-1, a transmem-
brane heparin sulfate proteoglycan involved in cell sig-
nalling, is associated with coagulopathy in severe sepsis 
[14]. Higher levels of syndecan-1 in plasma or serum 
indicate damage to the glycocalyx on the apical surface of 
endothelial cells [15].
Endothelial activation, mediated by dysregulation of 
the Ang/Tie2 axis and acute release of VWF, may pro-
duce a systemic microangiopathy in SM, contributing 
to morbidity and mortality. In this study, biomarkers 
of endothelial activation, haemostasis and thrombosis, 
including angiopoietin 1 and 2 (Ang-1 and Ang-2) lev-
els, VWF antigen, total active VWF, and ADAMTS13, 
platelet counts, syndecan-1 levels, and ApoA1 levels, 
were measured among Ugandan children with SM who 
participated in a clinical trial [16], in order to investigate 
associations between these processes.
Methods
Ethics and consents
Ethical approval was granted by the Makerere University 
School of Medicine Research Ethics Committee (Proto-
col #2010-107), the Uganda National Council for Science 
and Technology (Ref: HS857), the National Drug Author-
ity of Uganda (Ref:  297/ESR/NDA/DID-01/2011), and 
the University Health Network Research Ethics Com-
mittee, Toronto, Canada (UHN REB#10-0607-B). Writ-
ten informed consent was provided by an accompanying 
parent or caregiver for all study participants. The clinical 
trial from which participant samples derived was regis-
tered (Clinical trials.gov identifier: NCT01255215).
Patients and sample
One-hundred and eighty Ugandan children between the 
ages of 1 and 10  years who were admitted to the Jinja 
Regional Referral Hospital with SM were enrolled into a 
randomized controlled trial of adjunctive therapy with 
inhaled nitric oxide [16, 17]. Malaria was diagnosed 
by light microscopy of Giemsa-stained thick smears of 
EDTA-anticoagulated peripheral blood and by three-
band rapid diagnostic tests with Plasmodium falcipa-
rum histidine rich protein 2 (HRP2) and pan-malaria 
lactate dehydrogenase (pLDH) (First Response Malaria 
Ag. HRP2/pLDH Combo Rapid Diagnostic Test, Premier 
Medical Corp Ltd, India) [18].
SM was defined as malaria in patients experiencing 
repeated seizures (i.e., two or more generalized seizures 
in 24 h), prostration, impaired consciousness (i.e., Blan-
tyre coma score <5), or respiratory distress (i.e., age-
relative tachypnea with sustained nasal flaring, deep 
breathing or sub-costal retractions) [16]. Children were 
excluded from the trial if they had received quinine prior 
to enrolment, could not tolerate a mask for gas delivery, 
were suspected to have acute bacterial meningitis, or had 
methaemoglobin >2 % at baseline, known chronic illness 
(e.g., renal, cardiac, hepatitis disease, diabetes, epilepsy, 
cerebral palsy, haemoglobinopathy, or AIDS), or severe 
malnutrition (i.e., symmetrical oedema involving at least 
the feet or weight-for-length or height more than three 
standard deviations below the mean based on WHO 
reference charts). All children received intravenous 
artesunate. There was no effect of inhaled nitric oxide on 
treatment outcomes [16].
Blood was collected daily in plastic K2EDTA BD Micro-
tainer® tubes (New Jersey, USA) according to standard 
operating procedures. Briefly, 500 μL of blood was added 
to the microtainer tubes, which were then inverted ten 
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times, and centrifuged for 20  min at 4500  rpm before 
plasma was collected, taking care not to disturb the buffy 
layer, and transferred to cryovials for storage. Serum 
samples were collected in red-top tubes, in which blood 
was allowed to clot for 30–60 min before centrifugation 
for 20  min at 4500  rpm, followed by transfer to cryovi-
als for storage. Both plasma and serum were kept up to 
a maximum of 24 h at 4 °C before storing at −80 °C until 
use. Both sample types were collected at baseline day 1, 
day 2, day 3, day 4, and at day 14.
Laboratory testing, all participants
Baseline complete blood counts, including platelet 
counts, were obtained at a regional reference labora-
tory using a Beckman Coulter AcT 5 Diff hematology 
analyzer (Beckman Coulter, Inc, Fullerton, CA, USA). 
For the evaluation of change in VWF antigen over time, 
VWF antigen was measured in stored plasma samples 
from all study participants at all available time-points 
(i.e., through day 14 or death). Plates were coated with 
anti-human VWF antibody (DAKO North America, Inc, 
Carpinteria, CA, USA, 1:600 dilution), incubated with 
samples (1:1000 dilution) and standards (serial dilutions 
of recombinant VWF, American Diagnostica, Stamford, 
CT, USA), then incubated with HRP-conjugated anti-
human VWF (DAKO North America, Inc, Carpinte-
ria, CA, USA, 1:8000 dilution). Bound antibodies were 
detected with the HRP substrate tetramethylbenzidine, 
the reaction was stopped with H2SO4, then the colour 
signal was read at 450 nm. Background signal was deter-
mined from blank wells included on each plate (assay 
buffer added instead of sample), and background optical 
density was subtracted from all samples and standards 
prior to analysis. Samples with optical densities below 
the lowest detectable standard were assigned the value of 
that standard.
Laboratory testing, detailed subset
Baseline and day 4 serum samples from a sub-set of 12 
patients who survived until day 14 and had sample avail-
able were shipped to the López laboratory in Seattle. 
VWF multimer patterns were evaluated in the baseline 
serum samples of this participant subset and in pooled 
normal plasma by 1  % agarose gel electrophoresis fol-
lowed by Western blotting with a polyclonal VWF anti-
body, as described previously [19], and densitometry 
was quantified by ImageQuant TL software (GE Health-
care Bio-Sciences, Pittsburgh, PA, USA). For baseline 
and day 4 serum samples from this participant sub-set, 
VWF antigen levels were determined by ELISA using a 
polyclonal VWF antibody (DAKO North America, Inc, 
Carpinteria, CA, USA) as the capture antibody, with 
detection of bound VWF by an HRP-conjugated VWF 
antibody (DAKO North America, Inc, Carpinteria, CA, 
USA). VWF activation factor was determined by ELISA 
using llama nanobody AU/VWFa-11 as the capture anti-
body [20]. Total active VWF, a measure of total VWF 
reactivity, was calculated by multiplying VWF antigen 
(expressed as fold of the control sample) by VWF activa-
tion factor, as described by Chen et al. [21]. Ang-1, Ang-
2, ADAMTS13, and syndecan-1 levels were measured 
using commercially available ELISA kits (R&D Systems, 
Minneapolis, MN, USA) according to manufacturer’s 
instructions. The ApoA1 antigen level was measured 
by ELISA using a monoclonal ApoA1 antibody as the 
capture antibody and a horseradish peroxidase (HRP)-
conjugated polyclonal ApoA1 antibody as the detec-
tion antibody (LS-C11247 and LS-C11248, respectively, 
LifeSpan Biosciences, Inc, Seattle, WA, USA). Partici-
pant biomarker data for VWF antigen, total active VWF, 
ADAMTS13, ApoA1, and syndecan-1 were compared to 
data from plasma pooled from 20 normal donors (Cry-
ocheck Normal Reference Plasma, Precision Biologic, 
Dartmouth, NS, Canada) to determine fold-normal val-
ues for this analysis. Measurements of VWF antigen in 
serum and plasma are closely correlated (Chen, unpub-
lished observations).
Data analysis
All biomarker data were first tested for normality using 
the Shapiro–Wilk test, and log10-transformed to approxi-
mate normality if not normally distributed. Change in 
VWF antigen over time was evaluated in all 179 par-
ticipants for whom data were available after baseline, 
using overlaid longitudinal plots of VWF antigen by day 
of hospitalization. Generalized estimating equations 
(GEE) with a logit link and exchangeable correlation 
matrix were used to evaluate the association of VWF 
antigen levels with death. GEE with an identity link and 
exchangeable correlation matrix were used to evaluate 
change in VWF antigen levels by hospital day, overall and 
in survivors.
In the sub-set with detailed biomarker data, t tests were 
used to compare VWF antigen levels and total active 
VWF levels to the normal value expected (i.e., one-fold-
normal). Pair-wise correlations were calculated between 
all measured biomarkers at the pre-treatment baseline, 
and scatter plots with fitted regression lines were cre-
ated. Changes in each biomarker (except for platelets, 
which were not measured after baseline) between the 
pre-treatment baseline and day 4 were calculated, and 
pair-wise correlations were also calculated between these 
measures. Stata version 12.1 was used for analysis of data 
(Additional files 1, 2).
Page 4 of 9Graham et al. Malar J  (2016) 15:56 
Results
Results, all participants
At baseline, the geometric mean parasite density was 
17,399 (range, 0–696,320) parasites per μL. Of note, in 
ten cases, no parasites were seen on the admission blood 
smear, despite a positive-screening rapid diagnostic test 
result. In one other case, the species was diagnosed as 
Plasmodium ovale. In all of these cases, polymerase chain 
reaction testing performed on the red blood cell pellet 
was positive for P. falciparum. The mean platelet count 
was 106 (range, 2–489)  ×  109 per L, and mean VWF 
antigen level was 93.3 (range, 14.8–322.7) ng/mL. While 
parasite density was negatively correlated with platelet 
count (r = −0.234, p = 0.002) and positively correlated 
with VWF antigen (r = 0.178, p = 0.018), the correlation 
between platelet count and VWF antigen was not signifi-
cant (r = 0.095, p = 0.224).
Sixteen participants died during hospitalization, with 
14 of these deaths (87.5  %) occurring within 48  h of 
admission. Among the 179 participants for whom VWF 
antigen measures were available at baseline and during 
follow-up, there was a 3.39-fold (95 % confidence inter-
val (CI), 1.08–10.62, p = 0.036) increase in the odds of 
mortality for each unit increase in log10-transformed 
VWF antigen level. VWF antigen levels decreased by 
0.031 log10 ng/mL (95  % CI, 0.034–0.028 log10  ng/mL) 
per day overall and in the 163 survivors (p  <  0.001 for 
both analyses). Adjustment for treatment group (i.e., 
inhaled nitric oxide or control) did not change these 
results. VWF antigen data were available for the children 
who died at baseline for ten, day 2 for six, days 3 and 4 
for two, and day 14 for none. In several of these cases, 
VWF antigen levels actually increased over time before 
death. Figure 1 presents the change in VWF antigen lev-
els over time in non-survivors (panel A) and survivors 
(panel B).
Results, detailed sub‑set
Among the 12 participants with more detailed assess-
ments, baseline VWF levels (median 3.52-fold normal, 
range 1.72–4.67-fold normal, p < 0.0001) and total active 
VWF (median 6.25-fold normal, range 3.01–19.19-fold 
normal, p  =  0.0002) were both significantly elevated 
compared to normal. By agarose gel electrophoresis, sev-
eral patients had larger VWF multimers than those found 
in normal plasma, with two to four bands larger than the 
largest detected in pooled normal plasma by densitom-
etry analysis (Fig. 2).
Table  1 presents the absolute values of and correla-
tions between the biomarkers studied in baseline serum 
samples. While higher platelet counts were associated 
with higher log10- transformed Ang-1 (r = 0.62, p = 0.04) 
and ApoA1 levels (r = 0.61, p = 0.05), platelet count was 
inversely associated with syndecan-1 levels (r  =  −0.68, 
p  =  0.02). ApoA1 levels were inversely correlated with 
the log10-transformed Ang-2/Ang-1 ratio (r  =  −0.63, 
p  =  0.03) and with syndecan-1 levels (r  =  −0.68, 
p  =  0.01). As expected, Ang-2 and log10-transformed 
Ang-1 levels were both correlated with the log10-trans-
formed Ang-2/Ang-1 ratio.
Figure  3 presents scatterplots with fitted regression 
lines for the significant correlations identified at the pre-
treatment baseline. There were no correlations of plate-
lets, Ang-2 or Ang-1 levels or ratio, syndecan-1 levels, 
or ApoA1 levels with total active VWF, VWF antigen 
levels, or ADAMTS13 levels. In addition, there were no 
significant correlations between biomarkers with respect 
to change from the pre-treatment baseline to day 4 after 
treatment.
Fig. 1 Change in VWF antigen over time during hospitalization. 
Overlaid longitudinal plots were used to represent the change in VWF 
antigen levels over time in non-survivors (a) and survivors (b). Each 
line represents the data points for one participant. The blue line in b is 
a Loess estimation of the rate of decrease over time. Numbers on the 
X axis detail the number of subjects with data at each time point
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Discussion
In this study of Ugandan children with SM, higher VWF 
antigen levels were associated with an increased risk of 
mortality, and VWF antigen levels decreased in survivors 
but not in non-survivors for the limited time they were 
followed. In the sub-set of patients for whom detailed 
measurements were performed, platelet counts were pos-
itively correlated with log10-transformed Ang-1 and with 
ApoA1 levels (both protective factors), while platelet 
counts were negatively correlated with syndecan-1 lev-
els (indicative of endothelial glycocalyx damage). Higher 
log10-transformed Ang-2/Ang-1 ratio and higher synde-
can-1 levels, both indicative of endothelial activation and 
inflammation, were associated with lower ApoA1 levels. 
Although none of these measures correlated with VWF 
antigen, total active VWF, or ADAMTS13 levels, the 
SM patients in this study had elevated VWF levels and 
activity, with ultra-large multimers present in the serum 
of several patients. These findings reflect a state of VWF 
persistence and self-association, which increases platelet 
binding and the risks of thrombosis and microvascular 
occlusion.
In multiple field studies, this and other research 
groups have shown that altered levels of the endothelial 
regulators Ang-1 and Ang-2, as well as other markers of 
endothelial activation (e.g., soluble intercellular adhesion 
molecule-1, VWF antigen), are associated with malarial 
disease severity and mortality in both adults and children 
[22–27]. In these studies, Ang-2 was an independent and 
quantitative marker of malaria-related morbidity and 
mortality and a better predictor of outcome than other 
measures, including lactate. In a study of Malawian chil-
dren, Ang-1 and Ang-2 levels on admission were highly 
predictive of malarial retinopathy and CM [24]. Moreo-
ver, they were superior to retinopathy in predicting mor-
tality in children presenting with WHO-defined CM [24]. 
While a correlation between Ang-1 and platelet counts 
might be expected in serum due to release of platelet-
stored Ang-1 upon clot formation [28], both Ang-1 and 
Ang-2 levels in serum have been prognostically informa-
tive [22].
Very high plasma or serum concentrations of VWF, 
indicative of marked endothelial activation, have been 
previously described in SM caused by P. falciparum 
Fig. 2 VWF multimer distribution. The VWF multimer distribution was examined in baseline serum samples from either SM patients or pooled 
normal plasma (PNP) by electrophoresis on a non-reducing 1.7 % agarose-SDS gel, followed by western blotting. The Y axis shows the approximate 
number of VWF dimers at each level of the gel. Patients 2, 4, 5, 8–10, and 12 had larger VWF multimers than those found in normal plasma, with 
two to four larger bands (on top of the multimers) detected by densitometry analysis using ImageQuant TL software (GE Healthcare Bio-Sciences, 
Pittsburgh, PA, USA)
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infection [23, 29, 30]. In addition, VWF antigen levels 
have been reported to decrease with treatment [31]. A 
rapid rise in VWF such as was seen in some non-survi-
vors in this study, has been associated with a fall in the 
platelet count, a process that commences early after 
the onset of blood-stage infection [29]. As in the pre-
sent study, VWF antigen in plasma or serum during 
SM has been reported to be enriched in ultra-large and 
Fig. 3 Scatterplots with fitted regression lines. Data points are represented by individual dots, and the dashed line represents the fitted regression. 
The Pearson correlation and corresponding p value are also included. Panels present a platelet counts and log10-transformed Ang-1; b platelet 
counts and ApoA1 levels; c ApoA1 levels and log10-transformed Ang-2 to Ang-1 ratio; d ApoA1 levels and syndecan-1 levels; and e platelet counts 
and syndecan-1 levels
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hyperadhesive forms [29, 32]. While no associations were 
identified between VWF antigen, total active VWF, and 
ADAMTS13 and other biomarkers examined in the cur-
rent study, in  vitro studies have demonstrated that the 
ability of VWF to support platelet adhesion on intact 
endothelium is tightly controlled by competing pro-
cesses: specifically, the rates of VWF self-association and 
platelet binding versus the rate of ADAMTS13 cleavage 
[11, 13]. While little is known about the role of VWF self-
association in malaria, both VWF and platelets likely play 
an important pathophysiological role in SM, function-
ing to facilitate the attachment of infected erythrocytes 
and directly occluding the vessel. The role of glycocalyx 
damage in this process also merits further investigation, 
given the finding in this study of the inverse correlation 
between platelet counts and syndecan-1 levels.
In ongoing in  vitro studies, this research group has 
found that ApoA1 can potently inhibit VWF self-asso-
ciation and consequent platelet accumulation [13], and 
has also shown that in sepsis, ApoA1 levels correlate 
inversely with total active VWF [13]. Total active VWF 
is a parameter that takes into account both VWF anti-
gen concentration and adhesive activity, as determined 
by the binding of a llama nanobody that recognizes an 
epitope exposed in the VWF A1 domain when VWF 
binds to platelets [20]. Low ApoA1 levels could exac-
erbate the course of malarial infection in at least two 
ways. First, VWF strands will be more likely to accumu-
late on vessel walls and become resistant to proteolytic 
removal because of unabated self-association [13]. Sec-
ond, ApoA1 and HDL particles are necessary to pro-
tect prostacyclin, a potent platelet inhibitor, from rapid 
degradation, increasing the reactivity of platelets [33]. 
In this study, higher ApoA1 levels were associated with 
higher Ang-1 levels, and lower ApoA1 levels were asso-
ciated with a higher Ang-2/Ang-1 ratio. Lower ApoA1 
levels were also correlated with lower platelet counts and 
higher syndecan-1 levels, suggesting that lower ApoA1 
was associated with microvascular thrombosis and 
endothelial damage.
Several limitations of this study warrant discus-
sion. First, the study was conducted in the context of a 
randomized clinical trial of inhaled nitric oxide as an 
adjunctive treatment [16]. Clinical outcomes, including 
circulating angiopoietin 2 levels, did not differ by study 
arm [16], and adjustment for treatment group did not 
affect the analysis of change in VWF antigen over time. 
In addition, the detailed sub-set analysis focused on 
data from samples collected prior to the administration 
of nitric oxide or room air placebo. Second, no platelet 
counts were available after baseline, so it was not pos-
sible to evaluate how changes in VWF antigen over 
time or how detailed measures in the sub-set related to 
changes in platelet counts. Third, due to limited sample 
volume and the cost of additional assays, the sub-set in 
which detailed analyses were performed was limited. 
Nevertheless, this study has detected significant correla-
tions that highlight the importance of endothelial activa-
tion in SM.
Conclusion
These results confirm that SM is associated with 
endothelial activation and suggest that higher levels of 
endothelial activation are associated with microvascular 
thrombosis and endothelial damage. These findings may 
help elucidate pathogenic mechanisms of endothelial 
activation and microangiopathy in SM that could lead 
to the identification of new prognostic biomarkers and 
the development of therapeutic interventions. Further 
research to investigate causality and potential interven-
tions for these implicated pathways could address critical 
knowledge gaps in the understanding of the pathobiology 
of SM and facilitate the identification of clinically inform-
ative prognostic biomarkers, thereby enabling risk strati-
fication and targeting of interventions.
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